joined Neuren on October 1, 2006 and released on February 17, 2018;
see facebook here:
https://www.facebook.com/jamesbonnar
released by Neuren to enter Nyrada that has been set up by Noxo in recent months to study neurodegenative diseases like NNZ-2591.
this is his new preamble in Nyrada:
http://www.nyrada.com/site/About-Nyrada-Inc/management
is a chemist who is enabled to take the drug from preclinical to phase 2 with a toxicological study. in Neuren evidently for Rett and FX it has nothing more to do, but for NNZ-2591 yes; I therefore assume that either NNZ-2591 will be advanced by a staff other than Neuren unless Bonnar has decided to make a career elsewhere.
a few days are left and we will know many more things.
departure director, page-4
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.54 |
Change
0.680(3.42%) |
Mkt cap ! $2.626B | |||
| Open | High | Low | Value | Volume |
| $20.00 | $20.66 | $19.94 | $4.262M | 209.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 10 | $20.54 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.56 | 443 | 3 |
View Market Depth
| Last trade - 14.10pm 12/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |